Citi analyst P.J. Juvekar raised his price target for Chemours to $68 from $64 citing the company's "solid" Q4 results. The analyst thinks the shares were flat post-earnings dye to expectations that management would narrow or raise 2018 EBITDA guidance and concerns about the overhang related to environmental issues arising from filed litigation in Ohio and North Carolina. Juvekar, however, remains optimistic on future Opteon refrigerants growth as sales increased by 70% year-over-year in 2017. He raised his 2018-2020 earnings estimates for Chemours and keeps a Buy rating on the name.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here